trial · primary record
Efgartigimod IV or Efgartigimod PH20 SC
Generalized Myasthenia Gravis
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 12 |
| Primary completion | 2029-09 |
| Primary endpoint | Incidence of AEs, SAEs and AESIs |
| Registry ID | NCT05374590 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:42.856Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05374590
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.